SOURCE: Agennix AG

Agennix AG

November 19, 2010 06:29 ET

Agennix AG to Present at Two Investor Conferences in November

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - November 19, 2010) - Agennix AG (FRANKFURT: AGX) today announced that the Company will be presenting at two investor conferences in November.

The Company will give a presentation at the upcoming German Equity Forum (Eigenkapitalforum) in Frankfurt, Germany. The German Equity Forum is an investor conference hosted by the Deutsche Boerse and KfW SME Bank. The Company's presentation is scheduled for Tuesday, November 23, 2010 at 12:45 CET at the Congress Center Messe Frankfurt.

Agennix will also give a presentation at the 22nd Annual Piper Jaffray Health Care Conference in New York, NY. The presentation is scheduled for Tuesday, November 30, 2010 at 8:30 AM ET/14:30 CET at The New York Palace Hotel. A live audio webcast will be available through the Agennix Web site at www.agennix.com. A replay will be available on the Web site following the live event.

About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.

Contact Information

  • For further information, please contact:

    Agennix AG

    Investor Relations & Corporate Communications
    Phone: +49 (0)89 8565 2693
    ir@agennix.com

    In the U.S.:
    Laurie Doyle
    Director, Investor Relations & Corporate Communications
    Phone: +1 609 524 5884
    laurie.doyle@agennix.com

    Additional media contact for Europe:
    MC Services AG
    Raimund Gabriel
    Phone: +49 (0) 89 210 228 0
    raimund.gabriel@mc-services.eu

    Additional investor contact for Europe:
    Trout International LLC
    Lauren Williams
    Vice President
    Phone: +44 207 936 9325
    lwilliams@troutgroup.com